← FDA DRUG APPROVALS
FDA ANDA · ANDA208452
EMTRICITABINE, RILPIVIRINE, TENOFOVIR DISOPROXIL FUMARATE
Sponsor: MYLAN
APPLICATION
ANDA208452
TYPE
ANDA
ORIGINAL APPROVAL
2025-05-20
LATEST ACTION
2025-05-20
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
EMTRICITABINE, RILPIVIRINE AND TENOFOVIR DISOPROXIL FUMARATEPrescription
EMTRICITABINE 200MG, RILPIVIRINE HYDROCHLORIDE EQ 25MG BASE, TENOFOVIR DISOPROXIL FUMARATE 300MG · TABLET · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.